Follow-up of differentiated thyroid cancer: Comparison of multiple diagnostic tests

Nuclear Medicine Communications

Volumn 21, Issue 11, 2000, Pages 991-1000

  Dietlein, M ^a   Moka, D ^a   Scheidhauer, K ^a   Schmidt, M ^a   Theissen, P ^a   Voth, E ^a   Eschner, W ^a   Schicha, H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ALGORITHM; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; THYROID TUMOR; THYROIDECTOMY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; THYROID NEOPLASMS; THYROIDECTOMY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034332271     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200011000-00002     Document Type: Review

References (23)

1. 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 1997; 7: 265-271.
2. Mazzaferri EL, Jhiang SM. Longterm impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-428.
3. Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab 1992; 75: 714-720.
4. Schicha H, Dietlein M. Radioiodine therapy for well-differentiated thyroid carcinoma [in German]. Zentralbl Chir 1997; 122: 266-273.
5. Solomon BL, Wartofsky L, Burman KD. Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab 1996; 81: 333-339.
6. Sweeney DC, Johnston GS. Radioiodine therapy for thyroid cancer. Endocrinol Metab Clin North Am 1995; 24: 803-839.
7. Jeevanram RK, Shah DH, Sharma SM, et al. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Nucl Med Biol 1986; 13: 277-279.
8. Kao CH, Yen TC. Stunning effects after a diagnostic dose of iodine-131. Nuklearmedizin 1998; 37: 23-25.
9. 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun 1997; 18: 505-512.
10. Park HM, Park YH, Zhou XH. Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma. Thyroid 1997; 7: 277-280.
11. Park HM, Perkins OW, Edmondson JW, et al. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994; 4: 49-54.
12. Auffermann W, Clark OH, Thurnher S, et al. Recurrent thyroid carcinoma: characteristics on MR images. Radiology 1988; 168: 753-757.
13. 99mTc-MIBI oncoscintigraphy [in German]. Nuklearmedizin 1995; 34: 87-91.
14. Burman KD, Anderson JH, Wartofsky L, et al. Management of patients with thyroid carcinoma: application of thallium-201 scintigraphy and magnetic resonance imaging. J Nucl Med 1990; 31: 1958-1964.
15. Ohnishi T, Noguchi S, Murakami N, et al. Detection of recurrent thyroid cancer: MR versus thallium-201 scintigraphy. Am J Neuroradiol 1993; 14: 1051-1057.
16. Dietlein M, Scheidhauer K, Voth E, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997; 24: 1342-1348.
17. Dietlein M, Scheidhauer K, Voth E, et al. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm? Nuklearmedizin 1998; 37: 6-11.
18. Dietlein M, Dressler J, Farahati B, et al. Guidelines of the German Association of Nuclear Medicine: Guideline regarding radioiodine therapy for differentiated thyroid cancer [in German]. Nuklearmedizin 1999; 38: 221-222.
19. Barrington SF, Kettle AC, O’Doherty MJ, et al. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid. Eur J Nucl Med 1996; 23: 123-130.
20. Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer-a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992; 33: 1132-1135.
21. Feine U, Lietzenmayer R, Hanke JP, et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996; 37: 1468-1472.
22. 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997; 7: 327-335.
23. Grünwald F, Schomburg A, Bender H, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996; 23: 312-319.